Currently, several CLK or CLK2 inhibitors are being investigated in clinical trials for their potential use in treating various conditions such as degenerative diseases, osteoarthritis, cancers, psoriasis, scleroderma, and tendinitis (Qin et al., 2021). The gene discussed is CLK1; the disease is tendinitis.